OXFORD, England, September 16th 2014

PharmaVentures is pleased to announce the appointment of Dr Christopher Berry, formerly of Sanofi’s R&D Transactions Group, as an Associate in the corporate advisory team. Based in Paris, France, Dr Berry has negotiated 56 signed deals since 2010. Partners included universities, biotechnology companies and large pharmaceutical companies.

Dr Berry was responsible for building research collaborations in the areas of anti-infectives, biologics and regenerative medicine, as well as for the Asia-Pacific Therapeutic Unit. He was previously Head of Thrombosis and Haematology in Synthélabo Recherche, one of Sanofi’s predecessor companies. Dr Berry holds a PhD in Pharmacology from King’s College, London and an MBA from the Open Business School and is a fluent French speaker.

 Dr Fintan Walton, CEO, PharmaVentures said “We are delighted to have Dr Berry join us. His vast experience in early stage deal making will compliment our existing team and enable us to continue to offer our clients expert help throughout their deal making processes”.

 Dr Christopher Berry commented “Early stage deal making is essential as pharmaceutical companies strive to build competitive pipelines”.

 – ends –